Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults. The recommendations also apply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results